<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) is an inherited <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorder</z:e> caused by ataxin-3 with a polyglutamine expansion </plain></SENT>
<SENT sid="1" pm="."><plain>It is proposed that a toxic cleavage fragment of mutant ataxin-3 alternatively spliced isoform mjd1a triggers <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo>, although this fragment has not yet been detected in the brains of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients or in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>We have now generated transgenic mice expressing human mutant (Q71) or <z:mpath ids='MPATH_458'>normal</z:mpath> (Q20) ataxin-3 mjd1a under the control of the mouse prion promoter </plain></SENT>
<SENT sid="3" pm="."><plain>Q71 transgenic mice expressing mutant ataxin-3 mjd1a above a critical level developed a phenotype similar to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> including progressive <z:hpo ids='HP_0002172'>postural instability</z:hpo>, gait and <z:hpo ids='HP_0002070'>limb ataxia</z:hpo>, <z:hpo ids='HP_0001824'>weight loss</z:hpo>, premature <z:hpo ids='HP_0011420'>death</z:hpo>, <z:mp ids='MP_0004191'>neuronal intranuclear inclusions</z:mp>, and decreased tyrosine hydroxylase-positive neurons in the substantia nigra (determined by unbiased stereology) </plain></SENT>
<SENT sid="4" pm="."><plain>Q20 transgenic mice had <z:mpath ids='MPATH_458'>normal</z:mpath> behavior and pathology </plain></SENT>
<SENT sid="5" pm="."><plain>Brains from sick Q71 transgenic mice contained an abundant mutant ataxin-3 mjd1a putative-cleavage fragment (Fragment), which was scarce in <z:mpath ids='MPATH_458'>normal</z:mpath> Q71 transgenic mice </plain></SENT>
<SENT sid="6" pm="."><plain>Reactivity of the Fragment with a panel of antibodies and comigration with truncations of mutant ataxin-3 revealed that it contained residues C terminal to amino acid 221 to include the polyglutamine expansion </plain></SENT>
<SENT sid="7" pm="."><plain>A similar portion of mutant ataxin-3 mjd1a expressed in transfected <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> cells was toxic above a critical concentration </plain></SENT>
<SENT sid="8" pm="."><plain>The Fragment was more abundant in two affected brain regions of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, we have developed a murine model for mutant ataxin-3 mjd1a toxicity and identified a putative-cleavage fragment of the disease protein in the brains of these transgenic mice and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients that is cytotoxic above a critical concentration </plain></SENT>
</text></document>